MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
Key Details
- 1AI tools are advancing early detection in medical imaging, including lymph node metastases previously missed by standard diagnostics.
- 2Proton therapy is becoming more widespread, with phase III trials (e.g., 440 oropharyngeal cancer patients) showing reduced toxicities versus traditional radiation.
- 3Biomarker research is personalizing prostate cancer care, such as the NRG GU006 trial using genomic tools.
- 4Theranostics and radiopharmaceuticals, like FDA-approved Pluvicto, are expanding from localized to systemic radiation treatments.
- 5MD Anderson researchers are presenting over 65 abstracts at ASTRO covering these innovations.
Why It Matters
AI's integration into medical imaging is quickly improving diagnostic accuracy and treatment personalization in oncology. These advances—especially in clinical trials and real-world applications—are set to directly impact radiology workflows and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
MSK Research: Proton Therapy, AI Pain Summaries, and Tumor Metastasis Insights
MSK Cancer Center research advances include proton therapy for leptomeningeal metastasis and evaluating large language models for cancer pain summary.
•EurekAlert
Imaging AI Tool Predicts MS Drug Response Using Cell Morphology
Brazilian and French researchers have developed an imaging-based AI tool to predict how multiple sclerosis patients will respond to natalizumab treatment.
•EurekAlert
$16M PRISM Trial Launches to Evaluate AI in Breast Cancer Mammography
A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.